{"analyses":[{"ciLowerLimit":"40.44","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"57.64","estimateComment":"The 95% CI was computed using Anderson-Hauck method.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<.0001","paramType":"Difference in MRD Negativity Rates","paramValue":"49.04","statisticalMethod":"Chi-squared"},{"ciLowerLimit":"6.50","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"17.85","estimateComment":"OR was estimated using logistic regression model. The 95% CI was computed using Wald test.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Odds Ratio (OR)","paramValue":"10.77"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.90","upperLimit":"18.92","value":"13.3"},{"groupId":"OG001","lowerLimit":"55.15","upperLimit":"69.21","value":"62.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"194"}],"units":"Participants"}],"description":"MRD-negativity was defined as the presence of \\<1 malignant B-cell per 10000 normal B-cells in a sample of at least 200000 B-cells, as assessed by the allele specific oligonucleotide polymerase chain reaction (ASO-PCR) and/or flow cytometry technique. Percentage of participants with MRD-negativity was reported. The 95% CI was computed using Pearson-Clopper method. Percentage is rounded off.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received bendamustine at a dose of 70 milligrams per meter square (mg/m\\^2) via intravenous (IV) infusion on Days 1 and 2 of each 28-day cycle for 6 cycles, in combination with rituximab at a dose of 375 mg/m\\^2 via IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\\^2 on Day 1 of Cycles 2-6.","id":"OG000","title":"Bendamustine + Rituximab Main Study"},{"description":"Participants were initially placed on a venetoclax ramp-up period of 5 weeks and received an initial dose of 20 mg via tablet orally once daily (QD) for initial 1 to 7 days, then venetoclax dose was incremented weekly up to a maximum dose of 400 mg, orally, QD. Participants continued receiving venetoclax at a dose of 400 mg, orally, QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards up to PD or 2 years, whichever occurred first, as directed by the investigator, in combination with rituximab at a dose of 375 mg/m\\^2 via IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\\^2 on Day 1 of Cycles 2-6.","id":"OG001","title":"Venetoclax + Rituximab Main Study"}],"paramType":"NUMBER","populationDescription":"ITT population included all randomized participants, with participants grouped according to randomized treatment group, regardless of the actual treatment received.","reportingStatus":"POSTED","timeFrame":"EoCTR visit (8 to 12 weeks after C6D1); Cycle length = 28 days","title":"Percentage of Participants With Minimal Residual Disease (MRD) Negativity in Peripheral Blood","type":"SECONDARY","unitOfMeasure":"percentage of participants"}